Skip to content
NYSE · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · MID CAP

Usana Health Sciences Inc. USNA

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$925.3M
▲ 8.3% YoY
$10.8M
▼ 74.4% YoY
$8.5M
▼ 83.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

USANA Health Sciences, Inc. develops and manufactures nutritional supplements, functional foods and personal care products that are sold throughout the world. In 2025, it generated $925 million in net sales and finished the year with approximately 387,000 active Customers in its core nutritional business. It has operations in 25 geographic markets worldwide. As of January 3, 2026, it had approximately 1,570 employees working in 22 countries worldwide, as measured by full-time equivalency. It organizes its business into two reportable segments, Core nutritional and Hiya direct-to-consumer. Its Hiya direct-to-consumer segment operates and sells products to customers in the United States and, in 2026, is expanding into Canada and the United Kingdom. The company was founded in 1992 by Myron W. Wentz, Ph.D.

Written from the business description in USANA Health Sciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth

USD 925.3M
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.9 · Net income 0.0
0.5B1.0B
2009201220152018202120242025
Compound annual growth
−2.5%
−4.0%
+0.1%
+3.9%
−46.3%
−38.7%
−19.5%
−9.2%
−45.5%
−37.0%
+2.7%
−13.6%
−7.7%
+12.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −4.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 4.0% · Net 1.2%
5%10%15%
200920172025
ROE
FY2025 · ROE 2.0%
20%40%
200920172025
Three returns, three denominators.

Each USD of equity produced 2 cents of profit this year.

Cash & shareholders

USD 27.5M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 8.5
100M200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 27.5
100M200M
200920112013201520172019202120232025

USD 27.5M in buybacks — 256% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 742.9M
EquityUSD 533.1M
CashUSD 158.4M
Current ratio2.24×

Equity funds 72% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
USNA, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.90.90.91.01.21.11.11.21.01.00.90.80.70.60.60.50.4
Operating income $B0.00.10.10.10.20.20.10.20.10.10.10.10.10.10.10.10.1
EBITDA $B0.10.10.10.10.20.20.20.20.10.20.20.10.10.10.10.10.1
Income tax $B0.00.00.00.00.10.10.00.10.10.00.00.00.00.00.00.00.0
Net income $B0.00.00.10.10.10.10.10.10.10.10.10.10.10.10.10.00.0
Free cash flow $B0.00.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.0
EPS, diluted $0.582.193.303.595.735.864.415.122.533.993.592.805.564.453.262.862.17
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %2.08.213.716.727.831.427.133.518.233.037.131.235.437.031.641.345.1
Shares out B0.020.020.020.020.020.020.020.020.020.020.010.010.010.010.010.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNYSE
Incorporated inUtah
Fiscal year endsJanuary 3
Data on record since2009

Share this section

Download image